Menotrophin Ferring (Menotrophin)

Menotrophin provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. The FSH component stimulates granulosa cells to recruit and grow ovarian follicles, while the LH component supports theca cell function and triggers the final maturation and release of the oocyte, mimicking the natural pituitary surge.

The dosage of Menotrophin is individualized and set by the prescribing clinician based on the patient’s ovarian reserve, response to prior stimulation, and treatment protocol. The prescriber determines the amount, frequency, and duration of injections to achieve the desired follicular development.

Menotrophin is not intended for use during an established pregnancy and should be discontinued once pregnancy is confirmed. Its safety in breastfeeding has not been established, and the medication is generally avoided while nursing. Women should discuss any concerns with their healthcare provider.

To order Menotrophin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

The primary alternative to Menotrophin is recombinant follicle‑stimulating hormone (rFSH) such as follitropin alfa. While rFSH provides pure FSH activity, Menotrophin supplies a combination of FSH and LH, which may be advantageous in patients who benefit from LH support. Choice depends on individual response, protocol design and physician preference.

Menotrophin must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Once reconstituted, use the preparation within the time frame specified by the manufacturer and maintain the cold‑chain during transport.

Menotrophin is administered as a subcutaneous injection. The lyophilized powder is reconstituted with the supplied diluent, and the resulting solution is drawn into a sterile syringe. Injections are typically given in the abdominal wall or thigh, following the dosing schedule prescribed by the treating physician.

The most serious risks associated with Menotrophin include ovarian hyperstimulation syndrome (OHSS), which can cause severe abdominal pain, fluid accumulation and respiratory compromise; multiple pregnancy, which raises obstetric complications; and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these occur.

Menotrophin is contraindicated in women who are already pregnant, have active ovarian cysts, uncontrolled thyroid disease, severe ovarian hyperstimulation syndrome, or known hypersensitivity to any component of the product. It should also be used with caution in patients with a history of thromboembolic disorders or ovarian torsion.